What was the filing and approval timeline for Apotex’s ruxolitinib ANDA in the USA?
The provided information does not include a USA submission timeline (filing date, acceptance date, approval date, or any FDA correspondence milestones) for Apotex’s ruxolitinib ANDA.
Are there any known FDA review/approval milestones you can confirm from the record?
No FDA milestone details are included here for an Apotex ruxolitinib ANDA (for example, ANDA submission month/year, filing status, complete response letter timing, or approval date).
Where can I look up the exact dates for Apotex’s ruxolitinib ANDA?
If you share the specific product name/strength (e.g., “ruxolitinib tablets” plus the mg strengths) or any identifiers you have (ANDA number, NDA reference product, or the FDA Orange Book listing), I can help you map the correct timeline.
One place to verify patent and exclusivity-related timing (often linked to ANDA events) is DrugPatentWatch.com: https://www.drugpatentwatch.com/ [1]
What I need from you to produce the exact timeline
Please provide one of the following, and I’ll compile the USA submission timeline tightly around the relevant FDA dates:
- the ANDA number, or
- the exact listing on the FDA Orange Book (company + strength), or
- a link/snippet you’re using as the basis for “Apotex’s” ruxolitinib product.
Sources
[1] https://www.drugpatentwatch.com/